MEDICAL DEVICES · SERVICE DETAILS

Medical service U.S. services

U.S. agent designation, replacement, FDA liaison and information maintenance support for offshore facilities.

Applicability and scope of work are determined on the basis of products, business activities and available information, and costs and delivery are subject to mutually confirmed project arrangements.

SERVICE OVERVIEW

What does this service help with?

U.S. agent designation, replacement, FDA liaison and information maintenance support for offshore facilities.

WHO MAY NEED IT

Who should consider this service?

The manufacturer, labeler and team responsible for compliance in the United States market; Specific obligations are judged by the facts of the activities and products of each subject.

SCOPE & APPROACH

What we typically discuss

Identify information gaps before agreeing on documentation and responsibilities.

01

Designation and eligibility check

Check facilities, proxy United States contact addresses and physical contact arrangements, with clear designations and delegation of authority.

02

FDA Liaison and Inspection Arrangements

Assisting FDA in communicating with foreign facilities, answering questions about imported devices and arranging inspections; The enterprise appoints internal receivers to process them in a timely manner.

03

Confirmation and ongoing maintenance

Follow-up on FDA proxy confirmation, change and communication maintenance, and maintenance of confirmation and communication records.

GET READY

What to prepare before contacting us

If documents are incomplete, share the product and current stage first. You can provide the remaining details later.

  • Facilities and registration information
  • Existing agents and proposed changes
  • Day-to-day, emergency contacts and related FDA communications
HOW TO START

From initial review to engagement

STEP 01

Confirm product and project status

Check products, business roles, existing records and issues to be addressed.

STEP 02

Verification of information and agreed scope

Information gaps, responsibilities of the parties, costs and delivery arrangements are set out on this page.

STEP 03

Undertaking contractual work

Collaboration around the assessment, documentation, submission or maintenance of identified issues to be resolved.

STEP 04

Review and successor arrangements

Delivery of agreed records or recommendations with clear applicable responsibility for subsequent maintenance.

U.S. agent assumes the required liaison duties; This role does not assume responsibility for reporting or submitting 510(k) of 21 CFR Part 803. Other services are subject to a distinct delegation of authority and responsibility.

TIMING & FEES

Timing and fees

Information reviewed:Fee period: FY 2027, October 1, 2026 through September 30, 2027. For other charges, use the FDA rules as of the review date.

Timing and preparation

Document preparation

The facilities, existing agents, registration status, authorization and effective contact details are checked first to arrange for designation or replacement and contact handover.

FDA processing

FDA designation of recognition requirements should be followed by the instrument agent process; If consent is denied or no response is received within 10 working days, the facility will be required to appoint a new agent. The response period is not a guaranteed number of days of service.

Fee breakdown

FDA fees

U.S. agent service fees are agreed between the parties and are not user fees charged by the FDA for agent services; The registration, application or other application of the FDA for the facility on whose behalf the facility is represented is separately charged.

Service fees

Consulting and filing are quoted separately from FDA fees, based on the number of products, completeness of the records, work scope, response rounds and service term.

Other possible costs

Testing, translation, software and other third-party work are quoted separately where needed.

OFFICIAL SOURCES

FDA Official Basis and Check Date

Data check: 2026-11-05. The specific application conditions and submission requirements are based on the current official statement of the FDA and the product facts.

START WITH YOUR PRODUCT

Provide products and current information and confirm the next steps.

U.S. agent designation, replacement, FDA liaison and information maintenance support for offshore facilities.